Want to see TSE:CPH full AI Analyst Report?
CPH Stock Chart & Stats
C$16.25
-C$0.19(-1.16%)
At close: 4:00 PM EDT
C$16.25
-C$0.19(-1.16%)
Day’s Range― - ―
52-Week RangeC$11.98 - C$20.56
Previous CloseN/A
Volume9.58K
Average Volume (3M)26.25K
Market Cap
C$417.18M
Enterprise ValueC$462.58
Total Cash (Recent Filing)C$6.41M
Total Debt (Recent Filing)C$428.30K
Price to Earnings (P/E)9.5
Beta0.48
Next Earnings
Aug 06, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding25,391,321
10 Day Avg. Volume28,238
30 Day Avg. Volume26,255
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$22.00Price Target Upside35.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.9
Revenue Forecast (FY)C$53.46M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high net and operating margins indicate strong pricing power or a favorable product mix in core markets. High margins underpin durable internal funding for commercialization, support reinvestment in marketing or licensing, and improve resilience to modest revenue swings over a multi‑month horizon.
Strong Cash GenerationRapid free cash flow growth and near 1:1 conversion of earnings to cash provide ongoing funding for product launches, licensing deals, or working capital. Reliable FCF enhances strategic optionality and lowers reliance on external financing for growth initiatives over the next several quarters.
Conservative Balance SheetVery low net leverage and a strengthened equity base give the company financial flexibility to pursue licensing, distribution expansion, or opportunistic M&A without significant interest burden. This conservative structure supports long‑term investment and buffers cyclical revenue fluctuations.
Bears Say
Profitability VolatilityMaterial swings in reported profitability reduce predictability of sustainable earnings and complicate long‑range planning. If elevated margins reflect one‑offs or mix shifts, recurring profitability could be lower, making partner negotiations, budgeting, and long‑term cashflow forecasts less reliable over 2–6 months.
Cash Flow VariabilityWhile FCF is strong in aggregate, year‑to‑year variability and working capital timing effects create uncertainty in near‑term liquidity. This can require temporary financing or constrain discretionary spending in weaker quarters, reducing the consistency of reinvestment or partner support over the medium term.
Swinging Debt LevelsSignificant year‑to‑year changes in leverage suggest the capital structure is episodically adjusted, possibly for acquisitions or one‑time needs. This raises refinancing and policy consistency risks: recurring increases in debt could elevate interest exposure or limit flexibility if cash generation weakens.
Cipher Pharmaceuticals News
CPH FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was C$11.98 and its highest was C$20.56 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is C$417.18M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 7 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on May 07, 2026. The company reported C$0.338 earnings per share for the quarter, beating the consensus estimate of C$0.19 by C$0.148.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.29.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,391,321 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of C$0.338 in its last earnings report, beating expectations of C$0.19. Following the earnings report the stock price went up 10.464%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:CPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
CPH Company Deck
CPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all TSE:CPH earnings summariesCPH Stock 12 Month Forecast
Average Price Target
C$22.00
▲(35.38% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―